Medical marijuana licenses; establishing certain license criteria; establishing certain purpose; establishing certain fees. Effective date.
Summary
SB205 authorizes the Oklahoma Medical Marijuana Authority to create a new research license focused on patient-reported outcomes related to medical marijuana use. The bill is designed to support collection, analysis, and monitoring of data on how medical marijuana affects patients, including studies, surveys, and other data collection efforts that examine impacts on medical conditions.
The bill specifies who may qualify for this license: research institutions, health care organizations, licensed cannabis businesses, and private research companies. It also sets an initial nonrefundable application fee of $500 and directs the Authority to adopt rules governing license issuance, application approval, compliance monitoring, and reporting requirements. The act would take effect November 1, 2025.
Impact
SB205 would add a new research-license category to Oklahoma’s medical marijuana regulatory framework, codified as a new section in Title 63. It expands the Oklahoma Medical Marijuana Authority’s authority by allowing it to license entities for research on patient-reported outcomes and to regulate that activity through rulemaking, fees, compliance oversight, and reporting standards. The bill affects medical marijuana license applicants, research organizations, health care entities, and cannabis businesses seeking to participate in research.
Sentiment
Based on the bill text and the absence of recorded committee debate or votes, the overall sentiment appears neutral to supportive of research and data collection in the medical marijuana system. The measure is framed as an administrative and research-oriented expansion rather than a restrictive change, suggesting a policy interest in better understanding medical marijuana outcomes. No formal opposition, amendments, or recorded vote history is available in the provided materials.
Contention
The main potential points of contention are likely to involve the scope of who may conduct the research, how patient data and outcomes are collected and monitored, and whether licensed cannabis businesses should be allowed to participate alongside independent research institutions and health care organizations. Another possible issue is the adequacy of the $500 fee and the details of future rules, which are left to the Oklahoma Medical Marijuana Authority. However, no specific objections or supporter statements are included in the provided discussion materials.